Warburg Pincus has formed Constitution Medical Investors, a Boston-based acquisition platform focused on the healthcare sector. No financial terms of Warburg's equity commitment were disclosed. CMI will be led by former Cytec senior executives Patrick Sullivan and Daniel Levangie.
Constitution Medical Investors, Inc. (CMI), a Boston-based private investment firm focused on healthcare sector-related acquisitions and led by senior healthcare executives Patrick Sullivan and Daniel Levangie, today announced its formation in partnership with Warburg Pincus, the global private equity firm. Mr. Sullivan is the former President and Chief Executive Officer of Cytyc Corporation and, until recently, served as Executive Chairman of Hologic, Inc. (NASDAQ: HOLX), which acquired Cytyc in October 2007. Mr. Levangie previously was Executive Vice President of Cytyc Corporation and President of Cytyc's Surgical Products Division. He currently serves as a director of Hologic, Inc.
Constitution Medical Investors will focus on the identification and acquisition of innovative, healthcare-related platform technologies and companies where the principals will be able to leverage their product development, regulatory, clinical and commercial experience. Over the course of 15 years at Cytyc, one of the leading companies focused on improving healthcare for women, the CMI executive team helped grow the company to approximately $700 million in annual revenues and establish operations in 20 countries.
“Having helped to build Cytyc Corporation to its preeminent position in women's health, and with the integration of Cytyc with Hologic now complete, we are excited to put our extensive experience to work in a new venture,” said Mr. Sullivan. “We are proud of our track record of success in creating value in the healthcare marketplace, and we are very pleased to partner with Warburg Pincus, which will provide us with world-class support and resources that will allow us to once again make a real difference in improving medical care.”
“Pat and I have enjoyed a symbiotic business relationship for more than 20 years. I can't think of a partnership with more potential than what we have formed with CMI,” said Mr. Levangie.
Bess Weatherman, the Warburg Pincus Managing Director who leads the firm's investment activities in medical devices and healthcare services, said, “We are very excited to join Pat and Dan in the formation of CMI, and are eager to work with them in the identification of opportunities that will leverage their deep experience and industry know-how.”
Constitution Medical Investors is based in
About Constitution Medical Investors, Inc.
Constitution Medical Investors, Inc. is a Boston-based private investment firm focused on healthcare sector-related acquisitions, and launched in partnership with Warburg Pincus, the global private equity firm. CMI is led by Patrick Sullivan, formerly President and Chief Executive Officer of Cytyc Corporation and Executive Chairman of Hologic, Inc. (NASDAQ: HOLX), and Daniel Levangie, formerly Executive Vice President of Cytyc Corporation and President of Cytyc's Surgical Products Division. CMI focuses on the identification and acquisition of innovative, healthcare-related platform technologies and companies where the principals will be able to leverage their product development, regulatory, clinical and commercial experience. For more information, visit www.conmedinvestors.com.
About Warburg Pincus
Warburg Pincus has been a leading private equity investor since 1971. The firm currently has more than $35 billion of assets under management. Warburg Pincus' investments are focused on a range of sectors in North America, Europe and Asia, including financial services, healthcare, industrial, technology, media and telecommunications, energy, consumer and retail and real estate. Since inception, the firm has raised 12 private equity funds that have invested more than $31 billion in approximately 600 companies in more than 30 countries. The firm has invested $6.6 billion in healthcare-related companies around the world, including approximately $1.6 billion to help build nearly 40 biotechnology and pharmaceutical companies. The firm has an active global portfolio of more than 125 companies and offices in Beijing, Frankfurt, Hong Kong, London, Mumbai, New York, San Francisco, Shanghai and Tokyo. For more information, visit www.warburgpincus.com.